The University of Colorado completes exclusive option agreement to commercialise eyesight medical device to medtech Galaxy Ophthalmics.
The University of Colorado has exported rights to commercialise an implantable medical device to tackle the effects of glaucoma to local medtech firm Galaxy Ophthalmics. Glaucoma is the second leading cause of irreversible blindness on the planet, with over 60 million sufferers worldwide. It is a group of eye diseases that attack the optic nerve…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
